Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Aurinia Responds to Now Retracted LinkedIn Post

September 29, 2025 at 20:27 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today responded to a now retracted LinkedIn post referencing voclosporin by an FDA official.

Aurinia stands behind the favorable benefit/risk profile of LUPKYNIS^® (voclosporin). LUPKYNIS received full approval from the FDA in January 2021 based on a large, randomized 52-week clinical study known as AURORA 1. Furthermore, the FDA approved a supplementary new drug application for the long-term use of LUPKYNIS in April 2024 based on the results of AURORA 2, which demonstrated sustained efficacy of LUPKYNIS over a three-year period, with safety comparable to AURORA 1.

Please see Prescribing Information, including Boxed Warning, for LUPKYNIS.

About Aurinia

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS^®(voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.